← Back

Wire · regulatory

China's proposed technology export controls amendments: key takeaways for life sciences ...

Published

10 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at hsfkramer.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

China's Ministry of Commerce and Ministry of Science and Technology proposed amendments adding five categories of biomedicine technology to a restricted export list, including cell and gene therapy technology platforms and siRNA drug technology. The proposals prohibit ownership transfers of certain platform technologies while allowing licensing and outsourced R&D, with interim registration requirements effective from 16 October 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 23 sources have reported it between 16 Oct 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

You face tighter control on cross-border biotech tech around cell and gene therapy and siRNA platforms. Ownership transfers now trigger prohibition, so adjust deal structures to licensing or outsourced R&D to keep access open.

◆ Coverage

23 sources · first reported 16 Oct 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechchinaexport-controlsbiotechlife-sciencesregulation